BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

...the decision to stop the Phase I trial is consistent with its focus on solid tumors.Sihuan...
...span cancer, infectious diseases and metabolic disorders.  Financial terms were not disclosed. Xuanzhu is a unit of Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Mar 18, 2020
Product Development

COVID-19 roundup: BioNTech, Pfizer co-developing vaccine, plus updates from Regeneron, Novartis, CureVac, Fujifilm and CanSino

...Shanghai:600267) to treat influenza infection and a clinical trial application from the company for COVID-19. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Jun 19, 2019
Company News

Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more

...CMO and James Samuels as CFO. Li was VP of clinical development and CMO at Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Sep 5, 2018
Company News

Management tracks: Sihuan launches U.S. unit

Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:460) established a global business development unit in the U.S., through which it is seeking to expand and speed its international projects. The unit will be led by CBO Frank...
BioCentury | May 8, 2017
Distillery Therapeutics

Autoimmune disease

...Co. Inc. markets Atelec clinidipine, a long-acting dual L/N type calcium channel blocker, for hypertension. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Jan 11, 2016
Company News

RaQualia, Sihuan deal

...RaQualia and Sihuan’s Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered under a three-year deal to discover...
...RaQualia. The companies could not be reached for details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | May 4, 2015
Clinical News

Pirotinib: Phase I started

...patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), gastric and colorectal cancers. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

...additional animal models of AD. Mitsubishi Tanabe Pharma Corp. markets Radicut edaravone to treat stroke. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Apr 14, 2015
Clinical News

Sihuan begins U.S. pirotinib trial

...KBP5209 ) to treat advanced solid tumors including non-small cell lung, gastric and colorectal cancers. Sihuan...
...with Covance, the contract research subsidiary of Laboratory Corp. of America Holdings (NYSE:LH), to develop Sihuan's...
BioCentury | Apr 13, 2015
Company News

LabCorp, Sihuan deal

...research unit to develop Sihuan’s pipeline candidates. Covance will provide preclinical and clinical research services. Sihuan...
...The companies declined to disclose financial terms. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Sihuan Pharmaceutical Holdings Group Ltd....
Items per page:
1 - 10 of 18
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

...the decision to stop the Phase I trial is consistent with its focus on solid tumors.Sihuan...
...span cancer, infectious diseases and metabolic disorders.  Financial terms were not disclosed. Xuanzhu is a unit of Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Mar 18, 2020
Product Development

COVID-19 roundup: BioNTech, Pfizer co-developing vaccine, plus updates from Regeneron, Novartis, CureVac, Fujifilm and CanSino

...Shanghai:600267) to treat influenza infection and a clinical trial application from the company for COVID-19. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Jun 19, 2019
Company News

Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more

...CMO and James Samuels as CFO. Li was VP of clinical development and CMO at Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Sep 5, 2018
Company News

Management tracks: Sihuan launches U.S. unit

Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:460) established a global business development unit in the U.S., through which it is seeking to expand and speed its international projects. The unit will be led by CBO Frank...
BioCentury | May 8, 2017
Distillery Therapeutics

Autoimmune disease

...Co. Inc. markets Atelec clinidipine, a long-acting dual L/N type calcium channel blocker, for hypertension. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Jan 11, 2016
Company News

RaQualia, Sihuan deal

...RaQualia and Sihuan’s Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered under a three-year deal to discover...
...RaQualia. The companies could not be reached for details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | May 4, 2015
Clinical News

Pirotinib: Phase I started

...patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), gastric and colorectal cancers. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

...additional animal models of AD. Mitsubishi Tanabe Pharma Corp. markets Radicut edaravone to treat stroke. Sihuan Pharmaceutical Holdings Group Ltd....
BioCentury | Apr 14, 2015
Clinical News

Sihuan begins U.S. pirotinib trial

...KBP5209 ) to treat advanced solid tumors including non-small cell lung, gastric and colorectal cancers. Sihuan...
...with Covance, the contract research subsidiary of Laboratory Corp. of America Holdings (NYSE:LH), to develop Sihuan's...
BioCentury | Apr 13, 2015
Company News

LabCorp, Sihuan deal

...research unit to develop Sihuan’s pipeline candidates. Covance will provide preclinical and clinical research services. Sihuan...
...The companies declined to disclose financial terms. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Sihuan Pharmaceutical Holdings Group Ltd....
Items per page:
1 - 10 of 18